Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells
Fig 4
IVM inhibited pSMAD2 and pERK involved in the TGF-β signaling pathway in ER-positive and endocrine-resistant breast cancer cell lines: MCF-7, MCF-7/LCC2, MCF-7/LCC9.
(A) The protein levels were determined by Western blot after the treatment with various concentrations of IVM for 24 h. The graphs demonstrated the inhibitory effect of IVM as the fold change in protein levels of (B–D) pSMAD2/SMAD2 and (E–G) pERK/ERK in MCF-7, MCF-7/LCC2, and MCF-7/LCC9 cells, respectively. The data were shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001 compared with the nontreatment control (n = 3).